Would you recommend olaparib for a patient with germline BRCA1 mutation and HER2+ metastatic breast cancer who has progressed through multiple lines of HER2-directed therapy including trastuzumab deruxtecan?  


Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution